Tags : Etoposide

Roche’s Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA’s

Tuba Khan March 19, 2019

Shots: The approval is based on P-III IMpower133 study results assessing Tecentriq + CT vs CT as monothx. in 403 patients in ratio (1:1) with (ES-SCLC) The P-III IMpower133 study […]readmore

Tags : Etoposide

Roche’s Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA’s

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Etoposide

Roche’s Tecentriq (atezolizumab) + Chemotherapy (carboplatin and etoposide) Receive FDA’s

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company